申通快遞(002468.SZ):德殷德潤已完成工商註銷和新設分立程序
格隆匯 11 月 24日丨申通快遞(002468.SZ)公佈,公司近日接到公司股東通知,德殷德潤已完成工商註銷和新設分立程序,分立後的存續主體分別為上海德峨實業發展有限公司及上海德潤二實業發展有限公司。
上海德峨的註冊資本為人民幣796,017.1263萬元,股權結構為:德殷投資認繳和實繳的出資為329,519.2511萬元,佔註冊資本的41.40%;阿里網絡認繳和實繳的出資為466,497.8752萬元,佔注冊資本的58.60%。
德潤二的註冊資本為人民幣156,019.3537萬元,德殷投資認繳和實繳的出資為156,019.3537萬元,佔註冊資本的100%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.